Casdin Capital’s Rapport Therapeutics RAPP Stock Holding History
Bought
Maintained
Sold
Other funds holding RAPP
Casdin Capital's RAPP Position: Q3 2026 in Review
Casdin Capital opened a new position in Rapport Therapeutics (RAPP) in Q3 2026: 200,000 shares worth $6.72M. The stake represents 0.29% of the portfolio and ranks #36 among its holdings.
169 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.
- Casdin Capital held 200,000 shares of Rapport Therapeutics worth $6.72M as of Q3 2026.
- Rapport Therapeutics was a new Casdin Capital position in Q3 2026.
- Rapport Therapeutics made up 0.29% of Casdin Capital's portfolio in Q3 2026, its #36 holding.
- 169 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.
Based on Casdin Capital's 13F filing for Q3 2026, filed 16 Nov 2026.